Henrik Everberg
Directeur des opérations chez Pixelgen Technologies AB
Profil
Henrik Everberg is currently the Chief Operating Officer at Pixelgen Technologies AB since 2023.
Prior to this, he worked at Atlas Antibodies AB from 2011 to 2020 as the Head of Production & Logistics from 2015 to 2020.
Dr. Everberg obtained a doctorate degree from the University of Lund.
Postes actifs de Henrik Everberg
| Sociétés | Poste | Début |
|---|---|---|
Pixelgen Technologies AB
 Pixelgen Technologies AB BiotechnologyHealth Technology Pixelgen Technologies AB is a company that was founded in 2020 by a team of experienced innovators and entrepreneurs. The company is based in Solna, Sweden. Pixelgen has developed a DNA-based visualization technology called molecular pixelation, which analyzes cell surface proteins to gain insights into cellular activity. The Swedish company aims to deepen the understanding of biology for a healthier world with their technology. Pixelgen's products are covered by one or more claims of patents or pending patent applications. The company was founded by Johan Erik Simon Fredriksson, Alvaro Martinez Barrio, Filip Karlsson, and Fredrik Dahl, with Johan Erik Simon Fredriksson serving as the CEO since 2020. | Directeur des opérations | 12/09/2023 |
Anciens postes connus de Henrik Everberg
| Sociétés | Poste | Fin |
|---|---|---|
Atlas Antibodies AB
 Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Directeur des opérations | - |
Formation de Henrik Everberg
| University of Lund | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
Pixelgen Technologies AB
Pixelgen Technologies AB BiotechnologyHealth Technology Pixelgen Technologies AB is a company that was founded in 2020 by a team of experienced innovators and entrepreneurs. The company is based in Solna, Sweden. Pixelgen has developed a DNA-based visualization technology called molecular pixelation, which analyzes cell surface proteins to gain insights into cellular activity. The Swedish company aims to deepen the understanding of biology for a healthier world with their technology. Pixelgen's products are covered by one or more claims of patents or pending patent applications. The company was founded by Johan Erik Simon Fredriksson, Alvaro Martinez Barrio, Filip Karlsson, and Fredrik Dahl, with Johan Erik Simon Fredriksson serving as the CEO since 2020. | Health Technology |
